SINOVAC科兴董事长尹卫东先生在新冠疫苗合作国际论坛上的发言

尊敬的王毅国务委员，各位国际组织代表和部长阁下、各位科兴疫苗的合作伙伴，女士们，先生们：

大家好！很荣幸参加这次盛会，共谋未来。

在各国政府的支持下，在你们的领导下，科兴新冠疫苗克尔来福®已经在超过50个国家获得紧急使用或附条件上市，进入世界卫生组织紧急使用清单。科兴今年已经与中国以外的20个国家签约近9亿剂疫苗合作协议。这些疫苗不仅在中国生产，也分别在印尼的Bio Farma、巴西的布坦坦研究所，以及土耳其、马来西亚、埃及的合作伙伴生产。

当前，全球的新冠疫情还在上升，应对疫情的一大挑战是建立免疫屏障需要达到较高的疫苗接种率，而很多发展中国家接种率仍很低。

另一个重大挑战是新冠病毒的变异。最近多组研究数据提示Delta变异株有更高的传播率，变异的病毒正在挑战疫苗的保护效果。

面对这两大挑战，科兴需要与各国政府、疾病防控部门和科学家合作，给出解决方案。

首先，疫苗的安全性是提高疫苗接种率的重要因素。

在疫情风险高的地区或时期，人们可能会把疫苗的安全性放在次要地位，但现在全球都应该看到，当疫苗安全性达不到广大民众期望的时候，接种率很难达到形成免疫屏障的预期。因此，全球疫苗供应商都应把疫苗的安全性作为最重要的指标。

克尔来福®已经在全球完成超过10亿剂接种。克尔来福®可以说是安全性最好的新冠疫苗之一。科兴将通过保障克尔来福®的安全性，促进各国有更高的接种率，使控制新冠疫情的“炮弹”更多地发射出去。

其次，采取有效方式应对病毒变异株。

科兴已经完成了克尔来福第三针加强免疫的研究，接种第三针仍然像接种第一针和第二针一样安全，同时中和抗体水平可以在一周内快速地大幅度提升。中国科学院的科学家很快会在《科学》（Science）杂志上发表他们的新发现，加强免疫后疫苗对变异株的保护效果提高了。加强免疫后的真实世界研究已经在土耳其、智利等国展开，很快我们将获得结果。

科兴近期还将向各国药监局提交针对Gamma株的克尔来福®和Delta株的克尔来福®的临床研究及紧急使用申请。科兴有充足的生产能力提供不同种类的克尔来福®。

总之，提高克尔来福®的保护效果，使我们发出的“炮弹”不脱靶，是科兴不断努力的方向，也一定能做到！

新冠疫情没有国界，人类抗击疫情的战争也在不断变化，疫苗科学研究及供应领域的合作应该是永恒不变的致胜战略。科兴期待与各国更加信任、更长期的合作。科兴将为更多国家提供更多疫苗，愿意通过中国政府向发展中国家捐赠疫苗。

谢谢大家！

Chairman of Sinovac Yin Weidong’ Speech at the International Forum on Covid-19 Vaccine Cooperation Conference

Your Excellency Wang Yi , State Councilor and Foreign Minister;  

Your Excellencies Ministers, Representatives of International Organizations; 

Distinguished Partners of Sinovac, Ladies and Gentlemen,

Good Evening!

It gives me great pleasure to attend this International Forum on Covid-19 Vaccine Cooperation Conference today to seek a better future all together.

With the support of the governments of many countries and your strong leadership, Sinovac's COVID-19 vaccine has been granted an emergency use or conditional marketing authorization in more than 50 countries as well as being included in the emergency use list of World Health Organization. Sinovac has signed nearly 900 million vaccine cooperation agreements with 20 countries outside of China this year. These vaccines are not only manufactured in China, but are also jointly produced in BioFarma in Indonesia, Butantan Institute in Brazil as well as countries in Turkey, Malaysia, and Egypt.

Currently, the global Covid-19 epidemic is still spreading. A major challenge we are facing is to establish a herd immunity which requires a high vaccination coverage, however, the vaccination rate in many developing countries is still very low. Another major challenge is the new variants. Recently, a lots of research data show that the Delta strain has a higher transmission rate, and the mutated virus is challenging the vaccine effectiveness.

Facing these two major challenges, Sinovac needs to cooperate with governments, Disease Prevention and Control Departments and scientists to provide solutions.

Firstly, the safety of the vaccine is an important factor in increasing the vaccination rate.

In high-risk areas or periods, people are likely to put the safety of vaccines in a secondary concern, but now we all see that when the safety of vaccines does not meet the expectations of the general public, it is difficult to make the vaccination coverage to achieve the desired goal of herd immunity. Therefore, global vaccine suppliers should regard vaccine safety as the most important indicator.

So far, more than 1 billion doses of CoronaVac® have been administered worldwide, and it says CoronaVac® is one of the safest Covid-19 vaccines. Sinovac will ensure the safety of CoronaVac® and promote higher vaccination rates in all countries, so that we can shoot more "bullets” to control the Covid-19 epidemic.

Secondly, take effective measures to deal with new variants.

Sinovac has completed the study of the third dose of CoronaVac® on booster immunization. The third dose of vaccination is still as safe as the first and second doses. At the same time, the level of neutralizing antibodies can be rapidly increased within a week. Scientists from the Chinese Academy of Sciences will soon publish their new discoveries in scientific journal. After booster shot, the vaccine efficacy on the new variants is improved. Real-world Study after booster shot has been carried out in Turkey, Chile and other countries, and the results will be published soonest.

Sinovac will also submit our clinical research and emergency use applications for the Gamma and Delta strains of CoronaVac® to the National Medical Products Administration in coming days. Sinovac has sufficient production capacity to provide CoronaVac® developed and based on variants. 

In conclusion, Improving the efficacy of CoronaVac® to make sure our "Bullets do not miss the target, is the direction of Sinovac’s continuous efforts, and we believe that we can make it happen."

The Covid-19 can travel across borders, and the battle against the epidemic for human beings constantly changing. Cooperation in vaccine scientific research and development should be an eternal winning strategy. Sinovac looks forward to partnering with every country with more trust for longer-term cooperation. Sinovac will provide more vaccines to more countries!

Thank You！